Bruno Gagnon Email
SVP, Global Clinical Operations . Opthea
How to contact Bruno Gagnon
Join and see Bruno's contact info for free!Current Roles
Employees:
71Revenue:
$11MAbout
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic macular edema (DME), which remain leading causes of vision loss worldwide. \n\nOpthea’s lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D ‘trap’ inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. Sozinibercept has the potential to become the first therapy in 20 years to enable patients with wet AMD to live fuller and healthier lives.Opthea Address
South Yarra, null
AU